CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (unaudited) - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2022			145,565,916
Beginning balance at Dec. 31, 2022	$ 385,941	$ 11,483	$ 15	$ 1,226,267	$ (840,341)	$ 11,483
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation, net of tax withholding (in shares)			336,511
Stock-based compensation, net of tax withholding	3,868			3,868
Issuance of common stock, net of offering costs/At-the-Market offering (in shares)			21,357,175
Issuance of common stock, net of offering costs/At-the-Market offering	163,295		$ 2	163,293
Net income	118,699				118,699
Ending balance (in shares) at Mar. 31, 2023			167,259,602
Ending balance at Mar. 31, 2023	$ 683,286		$ 17	1,393,428	(710,159)
Beginning balance (in shares) at Dec. 31, 2023	242,829,391		242,829,391
Beginning balance at Dec. 31, 2023	$ 1,615,921		$ 24	2,183,537	(567,640)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation, net of tax withholding (in shares)			2,312,768
Stock-based compensation, net of tax withholding	51,041			51,041
Issuance of common stock, net of offering costs/At-the-Market offering (in shares)			24,663,351
Issuance of common stock, net of offering costs/At-the-Market offering	489,293		$ 3	489,290
Repurchase of shares in settlement of restricted stock (in shares)			(861,338)
Repurchase of shares in settlement of restricted stock	(16,535)			(16,535)
Net income	$ 337,173				337,173
Ending balance (in shares) at Mar. 31, 2024	268,944,172		268,944,172
Ending balance at Mar. 31, 2024	$ 2,476,893		$ 27	$ 2,707,333	$ (230,467)